UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 2, 2006
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of "accelerated filer and large accelerated filer" in
Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer X
Accelerated Filer Non-accelerated
filer
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At July 31, 2006, 7,291,451,351 shares of the issuer's
voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
July 2, 2006
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements:
Condensed
Consolidated Statements of Income for the three months and six months ended July 2,
2006 and July 3, 2005
Condensed
Consolidated Balance Sheets at July 2, 2006 and
December 31, 2005
Condensed Consolidated
Statements of Cash Flows for the six months ended July 2, 2006 and July 3,
2005
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
23
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
24
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
52
Item 4.
Controls and
Procedures
52
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
53
Item 1A.
Risk Factors
54
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
54
Item 3.
Defaults Upon
Senior Securities
55
Item 4.
Submission of
Matters to a Vote of Security Holders
55
Item 5.
Other
Information
55
Item 6.
Exhibits
55
Signature
56
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(millions
of dollars, except per common share data)
July 2,
2006
July 3,
2005
July 2,
2006
July 3,
2005
Revenues
11,741
11,452
23,488
23,595
Costs
and expenses:
Cost of sales(a)
1,790
1,762
3,461
3,639
Selling, informational and administrative expenses(a)
3,881
3,766
7,276
7,431
Research and development expenses(a)
1,742
1,830
3,285
3,547
Amortization of intangible assets
823
856
1,648
1,736
Merger-related in-process research and development
charges
513
260
513
262
Restructuring charges and merger-related costs
268
264
567
480
Other (income)/deductions - net
(359)
(198)
(615)
854
Income from continuing operations before provision/(benefit)
for taxes on income and minority interests
3,083
2,912
7,353
5,646
Provision/(benefit) for taxes on income
790
(464)
1,052
2,111
Minority interests
Income from continuing operations
2,290
3,375
6,296
3,531
Discontinued operations:
Income from discontinued operations - net
of tax
108
88
210
191
Gains on sales of discontinued
operations - net of tax
17
--
20
41
Discontinued operations - net of tax
125
88
230
232
Net income
2,415
3,463
6,526
3,763
Earnings
per common share - basic:
Income from continuing operations
0.31
0.46
0.86
0.48
Discontinued operations - net of tax
0.02
0.01
0.03
0.03
Net income
0.33
0.47
0.89
0.51
Earnings
per common share - diluted:
Income from continuing operations
0.31
0.46
0.86
0.48
Discontinued operations - net of tax
0.02
0.01
0.03
0.03
Net income
0.33
0.47
0.89
0.51
Weighted-average shares used to calculate earnings
per common share:
Basic
7,282
7,366
7,298
7,391
Diluted
7,305
7,418
7,330
7,445
Cash
dividends paid per common share
0.24
0.19
0.48
0.38
(a)
Exclusive
of amortization of intangible assets, except as disclosed in Note 12B, Goodwill
and Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
July 2,
2006*
Dec. 31,
2005**
ASSETS
Current Assets
Cash and cash
equivalents
1,921
2,247
Short-term
investments
12,829
19,979
Accounts
receivable, less allowance for doubtful accounts
9,275
9,103
Short-term
loans
511
510
Inventories
6,392
5,478
Prepaid
expenses and taxes
3,262
2,903
Assets of
discontinued operations and other assets held for sale
6,804
6,659
Total current assets
40,994
46,879
Long-term
investments and loans
2,387
2,497
Property, plant and equipment, less
accumulated depreciation
16,483
16,233
Goodwill
21,057
20,985
Identifiable
intangible assets, less accumulated amortization
26,134
26,244
Other assets,
deferred taxes and deferred charges
4,495
4,860
Total assets
111,550
117,698
LIABILITIES
AND SHAREHOLDERS' EQUITY
Current Liabilities
Short-term
borrowings, including current portion of long-term debt
3,779
11,589
Accounts
payable
1,740
2,073
Dividends
payable
1,757
1,772
Income taxes
payable
4,356
3,618
Accrued
compensation and related items
1,399
1,602
Other current
liabilities
5,655
6,564
Liabilities of
discontinued operations and other liabilities held for sale
1,369
1,237
Total current liabilities
20,055
28,455
Long-term debt
5,450
6,347
Pension benefit
obligations
2,721
2,681
Postretirement
benefit obligations
1,447
1,424
Deferred taxes
10,369
10,392
Other
noncurrent liabilities
3,019
2,635
Total liabilities
43,061
51,934
Shareholders' Equity
Preferred stock
152
169
Common stock
440
439
Additional
paid-in capital
68,217
67,759
Employee
benefit trust, at fair value
(700)
(923)
Treasury stock
(41,755)
(39,767)
Retained
earnings
40,627
37,608
Accumulated
other comprehensive income
1,508
479
Total shareholders' equity
68,489
65,764
Total liabilities and shareholders'
equity
111,550
117,698
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(millions
of dollars)
July 2,
2006
July 3,
2005
Operating Activities:
Net income
6,526
3,763
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization
2,694
2,776
Share-based compensation expense
326
79
Merger-related in-process research and development
charges
513
262
Intangible asset impairments and other associated
non-cash charges
--
1,213
Gains on disposal of investments, products and
product lines
(114)
(53)
Gains on sales of discontinued operations
(31)
(65)
Deferred taxes from continuing operations
(438)
(931)
Other deferred taxes
45
93
Other non-cash adjustments
219
215
Changes in assets and liabilities (net of businesses
acquired and divested)
(636)
(369)
Net
cash provided by operating activities
9,104
6,983
Investing
Activities:
Purchases of property, plant and equipment
(887)
(997)
Purchases of short-term investments
(5,663)
(7,441)
Proceeds from redemptions of short-term investments
13,239
12,570
Purchases of long-term investments
(248)
(560)
Proceeds from sales of long-term investments
47
568
Purchases of other assets
(78)
(99)
Proceeds from sales of other assets
Proceeds from the sales of businesses, products and
product lines
14
101
Acquisitions, net of cash acquired
(1,989)
(255)
Other investing activities
(116)
276
Net
cash provided by investing activities
4,322
4,169
Financing
Activities:
Increase in short-term borrowings, net
938
90
Principal payments on short-term borrowings
(10,583)
(5,800)
Proceeds from issuances of long-term debt
1,054
Principal payments on long-term debt
(2)
(22)
Purchases of common stock
(2,000)
(3,304)
Cash dividends paid
(3,468)
(2,930)
Stock option transactions and other
318
278
Net cash used in financing activities
(13,743)
(11,686)
Effect of exchange-rate changes on cash and cash
equivalents
(9)
Net decrease in cash and cash equivalents
(326)
(532)
Cash and cash equivalents at beginning of period
2,247
1,808
Cash and cash equivalents at end of period
1,921
1,276
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
921
1,296
Interest
414
329
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation
We prepared the condensed consolidated financial statements
following the requirements of the Securities and Exchange Commission (SEC) for
interim reporting. As permitted under those rules, certain footnotes or other
financial information that are normally required by accounting principles
generally accepted in the United States of America (GAAP) can be condensed or
omitted. Balance sheet amounts and operating results for subsidiaries operating
outside the U.S. are as of and for the three-month and six-month periods ended May 28,
2006 and May 29, 2005.
We made certain reclassifications to the 2005 condensed
consolidated financial statements to conform to the 2006 presentation. These
reclassifications are primarily related to discontinued operations (see Note
3, Discontinued Operations) as well as to better reflect jurisdictional
netting of deferred taxes.
Revenues, expenses, assets and liabilities can vary during
each quarter of the year. Therefore, the results and trends in these interim
financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements
included in this document. The financial statements include all normal and
recurring adjustments that are considered necessary for the fair presentation
of our financial position and operating results.
The information included in this Quarterly Report on
Form 10-Q should be read in conjunction with the consolidated financial
statements and accompanying notes included in Pfizer's Annual Report on
Form 10-K for the year ended December 31, 2005.
Note 2. Acquisitions
On May 16, 2006, we completed the acquisition of all of the outstanding
shares of Rinat Neuroscience Corp., a biologics company
with several new central-nervous-system product candidates. In
connection with the acquisition, as part of our preliminary purchase price
allocation, we recorded $478 million, pre-tax, in
Merger-related
in-process research and development charges.
On February 28, 2006, we completed the acquisition of the sanofi-aventis
world-wide rights, including patent rights and production technology, to
manufacture and sell Exubera, an inhaled form of insulin for use in adults with
type 1 and type 2 diabetes, and the insulin-production business and facilities
located in Frankfurt, Germany, previously jointly owned by Pfizer and
sanofi-aventis, for approximately $1.4 billion (including transaction
costs). In connection with the acquisition, as part of our preliminary purchase
price allocation, we recorded an intangible asset for developed technology
rights of approximately $1.0 billion, inventory valued at $218 million
and goodwill of approximately $166 million, all of which have been
allocated to our Human Health segment. The amortization of the developed
technology rights will be primarily included in Cost of Sales. Given
the size and complexity of the acquisition, the fair valuation and allocation
work is still being finalized and is expected to be completed in the third
quarter. To the extent that our estimates need to be adjusted, we will do so. Prior
to the acquisition, in connection with our collaboration agreement with
sanofi-aventis, we recorded a research and development milestone due to us from
sanofi-aventis of approximately $118 million ($71 million, after tax)
in the first quarter of 2006 in Research and development expenses upon
the approval of Exubera in January 2006 by the Food and Drug Administration
(FDA).
Note 3. Discontinued Operations
We evaluate our businesses and
product lines periodically for strategic fit within our operations. As a result
of our evaluation, we decided to sell a number of businesses and product lines,
certain of which qualified for Discontinued operations treatment:
In June 2006,
we entered into an agreement to sell our Consumer Healthcare business for
approximately $16.6 billion in cash. This business comprises
substantially all of our former Consumer Healthcare segment and other associated
amounts, such as purchase-accounting impacts and merger-related costs, and
restructuring and implementation costs related to our Adapting to Scale (AtS)
productivity initiative, previously reported in the Corporate/Other segment. In
addition, certain manufacturing facility assets and liabilities, which were
previously part of our Human Health or Corporate/Other segment, are included
in the planned sale of the Consumer Healthcare business. In connection with the
decision to sell this business, for all periods presented, the operating
results associated with this business that will be discontinued have been
reclassified into Discontinued operations - net of tax in the condensed
consolidated statements of income and the assets and liabilities associated
with this business that will be sold have been reclassified into Assets/Liabilities
of discontinued operations and other assets/liabilities held for sale, as
appropriate, on the condensed consolidated balance sheets. The divestiture of
the Consumer Healthcare business is expected to close in late 2006 and is
subject to customary closing conditions, including receipt of regulatory
approvals.
In the first
quarter of 2005, we sold the second of three European generic pharmaceutical
businesses, which had been included in our Human Health segment, for 70 million
euros (approximately $93 million) and recorded a gain of $57 million
($36 million, net of tax) in Gains on sales of discontinued
operations - net of tax in the condensed consolidated statement of
income. In addition, we recorded an impairment charge of $9 million ($6 million,
net of tax) related to the third European generic business in Income from
discontinued operations - net of tax in the condensed consolidated
statement of income for the six months ended July 3, 2005.
The following amounts, primarily
related to our Consumer Healthcare business, have been segregated from
continuing operations and included in Discontinued operations - net of tax in
the condensed consolidated statements of income:
Three
Months Ended
Six
Months Ended
(in millions)
July 2,
2006
July
3,
2005
July 2,
2006
July
3,
2005
Revenues
1,027
987
1,946
1,951
Pre-tax income
160
134
315
290
Provision for
taxes on income
(52)
(46)
(105)
(99)
Income from
operations of discontinued businesses - net of tax
108
88
210
191
Pre-tax gains on sales of
discontinued businesses
26
--
31
65
Provision for taxes on gains
(9)
--
(11)
(24)
Gains on sales
of discontinued businesses - net of tax
17
--
20
41
Discontinued operations-net of tax
125
88
230
232
The following assets and
liabilities, primarily related to our Consumer Healthcare business, have been
segregated and included in Assets of discontinued operations and other
assets held for sale and Liabilities of discontinued operations and
other liabilities held for sale, as appropriate, in the condensed consolidated
balance sheets:
(in millions)
July 2,
2006
Dec. 31,
2005
Accounts receivable, less allowance
for doubtful accounts
742
661
Inventories
567
561
Prepaid expenses and taxes
81
71
Property, plant and equipment - net
986
1,002
Goodwill
2,756
2,789
Identifiable intangible assets,
less accumulated amortization
1,643
1,557
Other assets, deferred taxes and
deferred charges
29
18
Assets of discontinued operations and
other assets held for sale
6,804
6,659
Current liabilities
610
538
Other
759
699
Liabilities of
discontinued operations and other liabilities held for sale
1,369
1,237
Net cash flows of our discontinued operations from each of
the categories of operating, investing and financing activities were not
significant for the six months ended July 2, 2006 and July 3, 2005.
Note 4. Adoption of New Accounting Standards
On January 1, 2006, we adopted the provisions of Statement
of Financial Accounting Standards (SFAS) No. 123R, Share-Based Payment, as
supplemented by the interpretation provided by SEC Staff Accounting Bulletin
(SAB) No. 107, issued in March 2005. (SFAS 123R replaced SFAS 123, Stock-Based
Compensation, issued in 1995.) We have elected the modified prospective
application transition method of adoption and, as such, prior-period financial
statements have not been restated. Under this method, the fair value of all stock
options granted or modified after adoption must be recognized in the consolidated
statement of income and total compensation cost related to nonvested awards not
yet recognized, determined under the original provisions of SFAS 123, must also
be recognized in the consolidated statement of income.
Prior to January 1, 2006, we accounted for stock options
under Accounting Principle Board Opinion (APB) No. 25, Accounting for Stock
Issued to Employees, an elective accounting policy permitted by SFAS 123.
Under this standard, since the exercise price of our stock options granted is
set equal to the market price on the date of the grant, we did not record any
expense to the condensed consolidated statement of income related to stock
options, unless certain original grant date terms were subsequently modified.
However, as required, we disclosed, in the Notes to Consolidated Financial
Statements, the pro forma expense impact of the stock option grants as if we
had applied the fair-value-based recognition provisions of SFAS 123.
The adoption of SFAS 123R primarily impacted our accounting
for stock options (see Note 14, Share-Based Payments).